<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke and dementias.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Burgunder JM, Finsterer J, Szolnoki Z, Fontaine B, Baets J, Van Broeckhoven C, Di Donato S, De Jonghe P, Lynch T, Mariotti C, Schols L, Spinazzola A, Tabrizi SJ, Tallaksen C, Zeviani M, Harbo HF, Gasser T, European Federation of Neurological Societies. EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias. Eur J Neurol. 2010 May;17(5):641-8. [28 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20298421&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Alzheimer's disease  (331.0); Dementia in conditions classified elsewhere without behavioral disturbance  (294.10); Ehlers-Danlos syndrome  (756.83); Epilepsy, unspecified, without mention of intractable epilepsy  (345.90); Hemiplegic migraine, without mention of intractable migraine without mention of status migrainosus  (346.30); Lipidoses  (272.7); Other and unspecified prion disease of central nervous system  (046.79); Unspecified cerebrovascular disease  (437.9); Vascular dementia, uncomplicated  (290.40)"/><FieldValue Value="MSH: Alzheimer Disease ; CADASIL ; Cerebral Amyloid Angiopathy ; Cerebrovascular Disorders ; Channelopathies ; Dementia ; DNA Mutational Analysis ; Ehlers-Danlos Syndrome ; Epilepsy ; Fabry Disease ; Frontotemporal Lobar Degeneration ; Genetic Counseling ; Genetic Testing ; Homocystinuria ; Lipidoses ; Migraine Disorders ; Molecular Diagnostic Techniques ; Prion Diseases ; Stroke "/><FieldValue Value="MTH: Alzheimer's Disease ; CADASIL Syndrome ; Cerebral Amyloid Angiopathy ; Cerebrovascular accident ; Cerebrovascular Disorders ; Dementia ; Ehlers-Danlos Syndrome ; Epilepsy ; Fabry Disease ; Frontotemporal Lobar Degeneration ; Genetic Counseling ; Genetic screening method ; Homocystinuria ; Lipoidosis ; Migraine Disorders ; Prion Diseases "/><FieldValue Value="PDQ: molecular diagnostic methods "/><FieldValue Value="SNOMEDCT_US: Alzheimer's disease  (26929004); Cerebral amyloid angiopathy  (230724001); Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy  (390936003); Cerebrovascular accident  (230690007); Cerebrovascular disease  (62914000); Dementia  (52448006); Ehlers-Danlos syndrome  (398114001); Epilepsy  (128613002); Epilepsy  (313307000); Epilepsy  (84757009); Fabry's disease  (124464003); Fabry's disease  (16652001); Familial hemiplegic migraine  (95656000); Genetic counseling  (79841006); Genetic screening, molecular method  (118124000); Genetic test  (405824009); Homocystinuria  (11282001); Lipoidosis  (10741005); Lipoidosis  (11455007); Migraine  (37796009); Molecular testing, diagnostic  (396927009); Multi-infarct dementia, uncomplicated  (191463004); Multi-infarct dementia, uncomplicated  (70936005); Prion disease  (20484008); Prion disease  (230284004)"/><FieldValue Value="UMD: Analyzers, Laboratory, Molecular Assay, Genetic Testing  (20-803)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Channelopathies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Epilepsies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cerebrovascular diseases (including stroke) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Migraine &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inherited dementias &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Screening" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Medical Genetics" /><FieldValue Value="Neurology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To summarize the possibilities and limitations of molecular genetic techniques and to provide diagnostic criteria for deciding when a molecular diagnostic work-up is indicated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with suspected genetic disorders including channelopathies, epilepsies, migraine, stroke and dementias&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assessment of clinical symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Genetic counseling &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Molecular genetic testing and mutation screening &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Proportion of cases of a clinically defined group of patients that are explained by a specific molecular diagnostic test&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To collect data about planning, conditions, and performance of molecular diagnosis of channelopathies, epilepsies, migraine, stroke and dementias, a literature search in various electronic databases, such as Cochrane library, MEDLINE, OMIM, GENETEST, or EMBASE was carried out and original papers, meta-analyses, review papers, and guideline recommendations were reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Evidence Classification Scheme for a Diagnostic Measure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: A prospective study in a broad spectrum of persons with the suspected condition, using a 'gold standard' for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class II&lt;/strong&gt;: A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by 'gold standard') compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IV&lt;/strong&gt;: Any design where test is not applied in blinded evaluation OR evidence provided by expert opinion alone or in descriptive case series (without controls).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The level of recommendations was based on the quality of available&#xA;studies, and the proportion of cases of a&#xA;clinically defined group of patients that are explained by a specific molecular diagnostic test was estimated.&#xA;As nearly all of these studies have a retrospective design and look for a specific mutation in a previously&#xA;ascertained and clinically diagnosed cohort of patients, the highest achievable recommendation level was B.&#xA;If only small case-series studying genotype&amp;ndash;phenotype correlations were available, the level of recommendation was C. If only case reports could be found, but experts still felt that they could give a recommendation, the level of recommendation was assessed as 'good practice point' (see the &quot;Rating Scheme for the Strength of the Evidence&quot; and the &quot;Rating Scheme for the Strength of the Recommendations&quot; fields).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Consensus about the recommendations was reached by a step-wise approach. First, task force members met at the European Federation of Neurological Societies (EFNS) congresses in 2007 and 2008 to discuss the preparations of the guidelines. In a second step, experts in genetics of the disorders wrote a guideline proposal. In a third step, these recommendations were distributed and discussed in detail among all task force members until a final consensus had been reached.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Rating of Recommendations for a Diagnostic Measure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A rating&lt;/strong&gt; (established as useful/predictive or not useful/predictive) requires at least one convincing class I study or at least two consistent, convincing class II studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B rating&lt;/strong&gt; (established as probably useful/predictive or not useful/predictive) requires at least one convincing class II study or overwhelming class III evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C rating&lt;/strong&gt; (established as possibly useful/predictive or not useful/predictive) requires at least two convincing class III studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Points (GPPs)&lt;/strong&gt; Where there was lack of evidence but consensus was clear the Task Force members have stated their opinion as good practice points.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guidelines were validated according to the European Federation of Neurological Societies (EFNS) criteria (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The levels of evidence (class I-IV) supporting the recommendations and ratings of recommendations (A-C, Good practice point [GPP]) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Channelopathies&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Muscular Channelopathies, Neuronal Channelopathies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There is good evidence to suggest that a thorough clinical and electrophysiological investigation may lead to the choice of the gene to be tested in patients with periodic paralysis &lt;strong&gt;(Level B)&lt;/strong&gt;. In myotonic disorders, it is recommended to first search for myotonic dystrophy and use clinical and electrophysiological phenotype characterization to guide for molecular genetic testing &lt;strong&gt;(Level B)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Molecular investigations are possible and may help in some cases to diagnose the condition but cannot be considered as a routine procedure with regard to the large number of different mutations in different genes. Furthermore, diagnosis can be made more easily by clinical and physiological investigations &lt;strong&gt;(Good Practice Point)&lt;/strong&gt;. One exception of note is the diagnosis of severe myoclonic epilepsy of infancy (SMEI), in which mutations are found in &lt;em&gt;SCN1A&lt;/em&gt; in 80% of the patients &lt;strong&gt;(Level B)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Cerebrovascular Diseases&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), Amyloid Angiopathies, Cavernous Malformations, Fabry's Disease, Homocystinuria, Ehlers-Danlos Syndrome&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Direct sequencing of exons 3 and 4 in the Notch3 gene is suggested as a first step if clinical suspicion for CADASIL is high &lt;strong&gt;(Level B)&lt;/strong&gt;. Cerebral amyloid angiopathy (CAA) should be considered in patients with early-onset, recurrent cerebral hemorrhages in association with prominent white matter lesions without classic clinical risk factors. In such cases, the &lt;em&gt;KRIT1&lt;/em&gt; gene should be screened for causative mutations &lt;strong&gt;(Level B)&lt;/strong&gt;. Genetic tests for Fabry's disease are suggested in the case of neuropathic pain, hypohidrosis, acroparesthesia, corneal opacities, cataract, renal failure, cardiac failure, ischaemic stroke, or transient ischemic attacks (TIAs) &lt;strong&gt;(Level B)&lt;/strong&gt;. Mutation screening in Ehlers-Danlos syndrome can be performed in case of clinical implications (easy bruising, hyperextensibility of joints, thin skin with visible veins, rupture of arteries, uterus or intestines, and arterial dissection) &lt;strong&gt;(Good Practice Point)&lt;/strong&gt;. In the event of a stroke attack with elevated level of serum homocysteine (&amp;gt;15 &amp;micro;M), screening for mutations in cystatione beta-synthetase and methylenetetrahydrofolate reductase is suggested &lt;strong&gt;(Level B)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Migraine&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Familial Hemiplegic Migraine (FHM)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The diagnosis of familial hemiplegic migraine can be confirmed with sequencing the hot spots of the most often affected gene (&lt;em&gt;CACNA1A&lt;/em&gt;) &lt;strong&gt;(Good Practice Point)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Inherited Dementias&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Alzheimer's Disease (AD), Frontotemporal Lobar Degeneration (FTLD), Prion Diseases&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the setting of a clinical diagnosis of AD, mutational screening first in &lt;em&gt;PSEN1&lt;/em&gt;, then in &lt;em&gt;APP&lt;/em&gt;, and finally (if negative) in &lt;em&gt;PSEN2&lt;/em&gt; can be useful for genetic counseling in cases of early-onset autosomal dominant AD &lt;strong&gt;(Level B)&lt;/strong&gt;. Genetic screening in sporadic cases with early onset can be considered &lt;strong&gt;(Good Practice Point)&lt;/strong&gt;. If the clinical diagnosis is that of a frontotemporal dementia, genetic testing for mutations in &lt;em&gt;PGRN&lt;/em&gt; and &lt;em&gt;MAPT&lt;/em&gt; is clearly indicated and useful for genetic counseling in patients with autosomal dominant FTLD &lt;strong&gt;(Level B)&lt;/strong&gt;, regardless of the presence or severity of extrapyramidal features. Testing can also be considered in familial and sporadic cases, although mutations are found only in &amp;lt;5% &lt;strong&gt;(Good Practice Point)&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evidence Classification Scheme for a Diagnostic Measure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: A prospective study in a broad spectrum of persons with the suspected condition, using a 'gold standard' for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class II&lt;/strong&gt;: A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by 'gold standard') compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IV&lt;/strong&gt;: Any design where test is not applied in blinded evaluation OR evidence provided by expert opinion alone or in descriptive case series (without controls).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Rating of Recommendations for a Diagnostic Measure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A rating&lt;/strong&gt; (established as useful/predictive or not useful/predictive) requires at least one convincing class I study or at least two consistent, convincing class II studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B rating&lt;/strong&gt; (established as probably useful/predictive or not useful/predictive) requires at least one convincing class II study or overwhelming class III evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C rating&lt;/strong&gt; (established as possibly useful/predictive or not useful/predictive) requires at least two convincing class III studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Points (GPPs)&lt;/strong&gt; Where there was lack of evidence but consensus was clear the Task Force members have stated their opinion as good practice points.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for selected recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate use of molecular genetics in diagnosing neurogenetic disorders&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;These guidelines are provisional, and the future availability of molecular genetic epidemiological data about the neurogenetic disorders under discussion in this article will allow improved recommendation with an increased level of evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;This guideline provides the view of an expert task force appointed by the Scientific Committee of the European Federation of Neurological Societies (EFNS). It represents a peer-reviewed statement of minimum desirable standards for the guidance of practice based on the best available evidence. It is not intended to have legally binding implications in individual cases. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The European Federation of Neurological Societies has a mailing list and all guideline papers go to national societies, national ministries of health, World Health Organisation, European Union, and a number of other destinations. Corporate support is recruited to buy large numbers of reprints of the guideline papers and permission is given to sponsoring companies to distribute the guideline papers from their commercial channels, provided there is no advertising attached.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Burgunder JM, Finsterer J, Szolnoki Z, Fontaine B, Baets J, Van Broeckhoven C, Di Donato S, De Jonghe P, Lynch T, Mariotti C, Schols L, Spinazzola A, Tabrizi SJ, Tallaksen C, Zeviani M, Harbo HF, Gasser T, European Federation of Neurological Societies. EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias. Eur J Neurol. 2010 May;17(5):641-8. [28 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20298421&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 May" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="European Academy of Neurology - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;European Federation of Neurological Societies&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;European Federation of Neurological Societies Task Force on the Molecular Diagnosis of Channelopathies, Epilepsies, Migraine, Stroke and Dementias&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Task Force Members&lt;/em&gt;: J-M. Burgunder, Department of Neurology, University of Bern, Bern, Switzerland; J. Finsterer, KA Rudolfstiftung, Vienna and Danube University, Krems, Austria; Z. Szolnoki, Department of Neurology and Cerebrovascular Diseases, Pandy County Hospital, Gyula, Hungary; B. Fontaine, Assistance Publique-H&amp;ocirc;pitaux de Paris, Centre de r&amp;eacute;f&amp;eacute;rence des canalopathies musculaires, Groupe Hospitalier Piti&amp;eacute;-Salp&amp;ecirc;tri&amp;egrave;re, Paris, France; J. Baets, Department of Neurology, University Hospital of Antwerp, Department of Molecular Genetics, VIB, and Laboratory of Neurogenetics, Institute Born-Bunge, and University of Antwerp, Antwerpen, Belgium; C. Van Broeckhoven, Department of Molecular Genetics, VIB, and Laboratory of Neurogenetics, Institute Born-Bunge, and University of Antwerp, Antwerpen, Belgium; S. Di Donato, Fondazione-IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy; P. De Jonghe, Department of Neurology, University Hospital of Antwerp, Department of Molecular Genetics, VIB, and Laboratory of Neurogenetics, Institute Born-Bunge, and University of Antwerp, Antwerpen, Belgium; T. Lynch, The Dublin Neurological Institute, Mater Misericordiae University, Beaumont &amp;amp; Mater Private Hospitals, Dublin, Ireland; C. Mariotti, Unit of Genetic of Neurodegenerative and Metabolic Diseases, IRCCS Foundation, Neurological Institute Carlo Besta, Milan, Italy; L. Sch&amp;ouml;ls, Clinical Neurogenetics, Center of Neurology and Hertie-Institute for Clinical Brain Research, University of T&amp;uuml;bingen, T&amp;uuml;bingen, Germany; A. Spinazzola, Division of Molecular Neurogenetics, IRCCS Foundation Neurological Institute Carlo Besta, Milan, Italy; S. J. Tabrizi, Department of Neurodegenerative Disease, Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; C. Tallaksen, Department of Neurology, Ullev&amp;aring;l University Hospital and Department of Neurology, Oslo University Hospital, Ullev&amp;aring;l, Oslo, Norway; M. Zeviani, Division of Molecular Neurogenetics, IRCCS Foundation Neurological Institute Carlo Besta, Milan, Italy; H. F. Harbo, Department of Neurology, Oslo University Hospital, Ulleval, Oslo, Norway; and T. Gasser, Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of T&amp;uuml;bingen and German Center for Neurodegenerative Diseases (DZNE), T&amp;uuml;bingen, Germany&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.efns.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2010_molecular_diagnosis_02.pdf&quot; title=&quot;EFNS Web site&quot;&gt;European Federation of Neurological Societies Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from J.-M. Burgunder MD, Department of Neurology, University of Bern, Inselspital, CH-3010 Bern, Switzerland; Phone: +41 31 352 20 70; Fax: +41 31 351 80 70; E-mail: &lt;a href=&quot;mailto:Jean-marc.burgunder@dkf.unibe.ch&quot;&gt;Jean-marc.burgunder@dkf.unibe.ch&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Brainin M, Barnes M, Baron JC, Gilhus NE, Hughes R, Selmaj K, Waldemar G; Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces &amp;ndash; revised recommendations 2004. Eur J Neurol. 2004 Sep;11(9):577-81. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.efns.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2004_neurological_management_guidelines.pdf&quot; title=&quot;EFNS Web site&quot;&gt;European Federation of Neurological Societies (EFNS) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Continuing Medical Education questions available from the &lt;a href=&quot;http://www.efns.org/%20EFNSContinuing-Medical-Education-online.301.0.html&quot; title=&quot;EFNS Web site&quot;&gt;EFNS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on August 8, 2011.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the Blackwell-Synergy copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
